Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01063322 · ClinicalTrials.gov registry record

New Techniques to Evaluate Mitral Regurgitation

A clinical trial of Mitral Valve Regurgitation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
50
Enrollment target
2
Study locations

NCT01063322: Completed study of Mitral Valve Regurgitation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT01063322 is a study of Mitral Valve Regurgitation that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 50 participants, below the 810-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01063322, a study of Mitral Valve Regurgitation, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

Background: \- Mitral regurgitation, or leaking of the mitral heart valve, is usually studied and assessed with an ultrasound test called a two-dimensional (2D) echocardiogram. While this test has proved very useful, technological improvements have helped researchers develop ways to study the heart valves using imaging with three-dimensional (3D) capabilities. In addition, recently developed magnetic resonance imaging (MRI) techniques may be able to provide better information about the causes and severity of the leak. Researchers are interested in testing these new techniques to determine their usefulness for patients with mitral regurgitation. Objectives: \- To evaluate newer methods of studying mitral regurgitation severity using real-time 3D echocardiography (RT3DE) and cardiac magnetic resonance imaging (CMRI). Eligibility: \- Individuals at least 21 years of age who have been diagnosed with more than mild mitral regurgitation. Design: * Participants will have two procedures as part of this study: an echocardiogram and an MRI scan. * For the echocardiogram, participants will have an ultrasound scan with a special kind of probe. Participants may also receive an injection of a contrast agent to provide a better image of the heart on the scan. The scan will take approximately 1 hour to complete. * For the MRI scan, participants will have a standard MRI with special pads placed on the chest to provide better imaging of the heart. The scan will usually take between 45 and 90 minutes to complete.

Conditions Studied

Study Locations (2)

Maryland

  • Suburban Hospital - Bethesda
  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-02-01
Est. Completion 2018-04-11

What the finished NCT01063322 record still lists

NCT01063322 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 810-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 0 interventions.

NCT01063322 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01063322 about?

NCT01063322 is a clinical study titled "New Techniques to Evaluate Mitral Regurgitation". Background: \- Mitral regurgitation, or leaking of the mitral heart valve, is usually studied and assessed with an ultrasound test called a two-dimensional (2D) echocardiogram. While this test has proved very useful, technological improvements have helped researchers develop ways to study the heart...

What is the current status of trial NCT01063322?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2010-02-01. Estimated completion is 2018-04-11.

What conditions does trial NCT01063322 study?

This clinical trial studies the following conditions: Mitral Valve Regurgitation.

Who is sponsoring clinical trial NCT01063322?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01063322 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Valve Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01063322's enrollment target sits among peer trials

50 10th of 11 higher than 2 of 11 other Mitral Valve Regurgitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mitral Valve Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01063322, the US trial registry maintained by the National Library of Medicine. NCT01063322 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.